Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN; NAPROXEN SODIUM vs FROVATRIPTAN SUCCINATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.
Acute treatment of migraine attacks with or without aura in adults
Acute treatment of migraine with or without aura in adults
Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.
2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.
Sumatriptan: terminal half-life approximately 2.5 hours (range 1.5–4.6 hours); clinically, short half-life limits duration of action. Naproxen sodium: terminal half-life approximately 12–17 hours (mean 14 hours); long half-life allows twice-daily dosing and sustained analgesic effect.
Terminal elimination half-life is approximately 4-5 hours (range 3-6 hours). This relatively short half-life supports its use for acute migraine treatment, though it may allow for repeat dosing within 24 hours if necessary.
Sumatriptan is primarily metabolized by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9.
Primarily hepatic via CYP1A2; undergoes oxidative metabolism; some contribution from CYP2D6.
Sumatriptan: renal excretion of unchanged drug and metabolites (primarily indole acetic acid analogue) accounts for approximately 60% of elimination; fecal/biliary excretion accounts for about 40%. Naproxen sodium: renal excretion of unchanged drug (approximately 60%) and glucuronide conjugates (about 40%); less than 5% is excreted fecally.
Primarily hepatic metabolism via CYP1A2; renal excretion accounts for ~10% of unchanged drug. Total recovery in urine and feces is ~90% over 72 hours, with ~30% in urine (mostly metabolites) and ~60% in feces.
Sumatriptan: protein binding approximately 14–21% (low binding). Naproxen sodium: protein binding >99% (highly bound to albumin).
Approximately 30% bound to plasma proteins, primarily albumin. Low protein binding suggests minimal displacement interactions.
Sumatriptan: Vd approximately 2.2 L/kg (indicates extensive tissue distribution). Naproxen sodium: Vd approximately 0.16 L/kg (low Vd, consistent with high protein binding and limited tissue distribution).
Mean volume of distribution is approximately 2.7 L/kg, indicating extensive extravascular distribution, consistent with its CNS penetration for migraine relief.
Sumatriptan: oral bioavailability approximately 15% (due to first-pass metabolism); subcutaneous injection 96%; intranasal approximately 17%. Naproxen sodium: oral bioavailability >95% (well absorbed).
Oral bioavailability is approximately 30% due to first-pass metabolism. No other routes are clinically approved; the drug is only available orally.
Contraindicated if GFR <30 m L/min; for GFR 30-50 m L/min, caution with naproxen component; no specific dose adjustment recommended for sumatriptan.
Contraindicated in severe renal impairment (Cr Cl <15 m L/min). For moderate impairment (Cr Cl 15-29 m L/min), maximum dose 2.5 mg per 24 hours. No adjustment for mild impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C); sumatriptan maximum dose 50 mg per dose in moderate impairment (Child-Pugh class B); naproxen sodium avoid in severe impairment.
Contraindicated in moderate to severe hepatic impairment (Child-Pugh class B or C). For mild impairment (Child-Pugh class A), no dose adjustment required.
Not approved for patients <12 years; for adolescents 12-17 years, single dose of sumatriptan 85 mg / naproxen sodium 500 mg (as adult formulation) per clinical judgment, not to exceed 1 dose in 24 hours.
Safety and efficacy not established in pediatric patients under 18 years of age.
Avoid use in elderly due to increased risk of cardiovascular events, gastrointestinal bleeding, and renal impairment; if necessary, use lowest effective dose for shortest duration.
No specific dose adjustment recommended based on age alone, but use with caution due to increased risk of adverse effects (e.g., cardiovascular events) and potential age-related renal impairment.
Cardiovascular and gastrointestinal risks: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. NSAIDs also increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Sumatriptan is contraindicated in patients with history of coronary artery disease or risk factors. Do not use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication.
Not recommended for use in patients with risk factors for coronary artery disease (CAD) unless a cardiovascular evaluation confirms absence of CAD.
Cardiovascular events: Myocardial ischemia, infarction, arrhythmia, and death reported with sumatriptan. NSAIDs increase risk of serious cardiovascular thrombotic events.,Gastrointestinal effects: NSAIDs increase risk of GI bleeding, ulceration, and perforation.,Excessive use: Medication overuse headache may occur.,Serotonin syndrome: Risk with concurrent use of serotonergic drugs.,Renal effects: NSAIDs can cause renal toxicity.,Hypertension: Sumatriptan may increase blood pressure.,Anaphylactic reactions: Serious allergic reactions including anaphylaxis reported with sumatriptan.,Hepatic effects: NSAIDs may cause liver enzyme elevations.
Serious cardiac events including myocardial ischemia, infarction, and arrhythmias; cerebrovascular events including stroke; serotonin syndrome when coadministered with serotonergic drugs; increases in blood pressure; peripheral vascular ischemia; medication overuse headache; severe hepatic impairment.
History of coronary artery disease (CAD) or coronary artery vasospasm,Wolff-Parkinson-White syndrome or other cardiac accessory pathway disorders,History of stroke or transient ischemic attack,Peripheral vascular disease,Ischemic bowel disease,Uncontrolled hypertension,Within 24 hours of treatment with another 5-HT1 agonist (e.g., triptans) or ergotamine-containing medications,Concomitant use or within 2 weeks of MAO-A inhibitor,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In the setting of coronary artery bypass graft (CABG) surgery,Third trimester of pregnancy
Ischemic heart disease; history of myocardial infarction; coronary artery vasospasm; uncontrolled hypertension; hemiplegic or basilar migraine; concomitant use with ergotamines or 5-HT1 agonists; severe hepatic impairment; hypersensitivity to frovatriptan.
Avoid alcohol (may exacerbate migraine and increase GI irritation). Limit caffeine intake (can trigger migraine). No specific food restrictions, but maintain hydration.
No specific food interactions. Avoid alcohol as it can exacerbate migraine and increase sedation risk. Grapefruit juice may increase frovatriptan levels due to CYP1A2 inhibition; limit or avoid consumption.
Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction and reduced placental perfusion. Naproxen: First trimester – potential increased risk of cardiac defects; second trimester – generally safe with caution; third trimester – contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal dysfunction.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal variations) at doses ≥50 mg/kg/day (approximately 100 times the MRHD). Increased risk of maternal toxicity (reduced weight gain) at high doses. Potential risk of uterine contractions and reduced uterine blood flow due to vasoconstrictive properties. Use only if potential benefit justifies risk to fetus.
Sumatriptan: Excreted in breast milk with estimated relative infant dose of 3.5% of maternal weight-adjusted dose; M/P ratio not well defined. Naproxen: Excreted in breast milk with M/P ratio approximately 0.01; relative infant dose <1% of maternal dose. Both considered compatible with breastfeeding with monitoring for infant adverse effects.
Excreted in rat milk; no human data. M/P ratio unknown. Caution recommended due to potential adverse effects in nursing infants (e.g., vasoconstriction, serotonin syndrome). Decision to breastfeed or discontinue drug should consider importance of drug to mother.
No specific dose adjustments recommended for sumatriptan in pregnancy; however, limited data suggest no significant pharmacokinetic changes. Naproxen: Clearance may increase in later pregnancy; dose adjustments not well studied. Avoid naproxen in third trimester.
No specific pharmacokinetic studies in pregnancy. Dose adjustment not established; use lowest effective dose. Caution in third trimester due to possible uterine vasoconstriction. Consider alternative therapy if frequent use needed.
Sumatriptan/naproxen sodium is contraindicated within 24 hours of another triptan or ergotamine. Naproxen dose is fixed; avoid additional NSAIDs to prevent GI bleeding or renal impairment. Use with caution in patients with cardiovascular risk factors. Onset of action is 10-30 minutes; advise against driving if dizziness occurs.
Frovatriptan has a long half-life (~26 h), making it useful for prolonged migraine attacks or for menstrual migraine prophylaxis when dosed perimenstrually. Onset is slower than other triptans; not ideal for acute severe migraine requiring rapid relief. Contraindicated with MAOIs, potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), and within 24 h of another triptan or ergotamine. Avoid in patients with hemiplegic or basilar migraine, ischemic heart disease, or uncontrolled hypertension.
Take at the first sign of migraine; do not exceed one tablet in 24 hours.,Do not take within 24 hours of other triptans or ergotamine-containing drugs.,Avoid alcohol during migraine attack as it may worsen symptoms.,Report chest tightness, palpitations, or shortness of breath immediately.,Do not drive or operate machinery if feeling dizzy or drowsy.,Inform healthcare provider of all medications, especially blood thinners or antidepressants.
Take frovatriptan at the first sign of a migraine headache, not during the aura or for prevention of typical migraines.,Swallow tablets whole with water; do not crush or chew.,If the headache returns after initial relief, a second dose may be taken after at least 2 hours, with a maximum of 3 tablets per 24 hours.,Do not use frovatriptan if you have taken another triptan or ergotamine within the last 24 hours.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness).,Avoid alcohol during use as it may worsen headache or increase side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver or kidney disease.,Do not drive or operate machinery until you know how frovatriptan affects you, as it may cause dizziness or drowsiness.
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN; NAPROXEN SODIUM vs FROVATRIPTAN SUCCINATE, answered by our medical review team.
SUMATRIPTAN; NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.. FROVATRIPTAN SUCCINATE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN; NAPROXEN SODIUM and FROVATRIPTAN SUCCINATE depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN; NAPROXEN SODIUM is: Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.. The standard adult dose of FROVATRIPTAN SUCCINATE is: 2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN; NAPROXEN SODIUM and FROVATRIPTAN SUCCINATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN; NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction an. FROVATRIPTAN SUCCINATE is classified as Category D/X. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal varia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.